reason report
day confer call discuss approv price access
zolgensma unit state manag indic
zolgensma royalti book up-front though full detail
implic royalti avail note cfo
present call up-front revenu recognit suggest
like receiv royalti novarti first year
treatment rather spread annual payment consist
payment structur current model though nv
unabl confirm call ask look
disclosur novarti manag clariti royalti payment
time potenti patent term extens file us
geographi potenti royalti impact value-bas
agreement reiter pt under-perform rate
share await addit feedback
major annuiti payment book up-front nv
indic plan recogn zolgensma revenu
up-front even though zolgensma paid annual instal
detail would affect royalti
hand call recogn bulk zolgensma revenu
up-front impli receiv royalti
payment shortli dose undermin bear thesi
receiv full royalti patient treat zolgensma
patent expiri approach addit term value-bas
agreement effect royalti still unclear point
though novarti manag indic payment
risk value-bas agreement driven medicaid best
price limit potenti downsid royalti cash flow treatment
capac treat elig incid preval patient
patient spinal muscular atrophi sma elig treatment
zolgensma on-label anoth born year nv
indic compani suffici manufactur capac treat
elig patient eu jp launch manufactur
expect bottleneck zolgensma uptak
institut readi administ zolgensma product readi
ship two week though novarti still discuss payer
reimburs term value-bas agreement
novarti manag access program indic patient may
pois switch spinraza compani manag access
program patient treat spinraza prior
zolgensma administr indic much preval
sma popul two year age current treat
spinraza consist estim high spinraza penetr
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep dilut
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
popul certainli dont expect preval
patient treat zolgensma spinraza switcher introduct
zolgensma may begin lower spinraza complianc new
patient start move forward look mp
confer call first look dynam spinraza
rate share under-perform optimist
blockbust believ current valuat account robust royalti stream
sale spinal muscular atrophi sma partner asset ascrib substanti valu
compani wholli own pipelin see challeng clinic practic wet
unclear commerci potenti mucopolysaccharidos
type ii mp mp ii optimist homozyg famili
hypercholesterolemia hofh though departur rgnx rais concern clinic
price target base dcf methodolog forecast risk-
adjust sale risk-adjust royalti
key partner program explicitli model expens result cash flow
assum discount rate consist clinic stage pre-revenu compani
coverag univers termin growth rate addit includ rgnx net cash
balanc valuat
risk view outlook valuat inc includ major chang
price reimburs coverag gene therapi agent unexpect safeti efficaci
signal clinic develop chang regulatori environ forecast subject
unmodel competitor entrant includ gene edit disrupt technolog
could potenti compet share aav-bas therapi develop partner
convers sale royalti forecast includ estim impact certain competit
agent agent fail enter market poorer-than-expect clinic profil
otherwis fail garner share expect could repres materi upsid
estim element compani busi model depend monet
core ip asset chang intellectu properti law enforc compani ip
portfolio could materi impact compani prospect futur cash flow
total cost revenu
research develop
gener administr
sale market
loss incom oper
interest incom licens
total incom expens
loss incom tax
compani report svb leerink equiti research estim
sale market product revenu
compani report leerink equiti research estim
bs mm
cash equival
properti equip net
accru expens current liabil
defer rent net current portion
accumul comprehens loss incom
total liabil stockhold equiti
chang
oper
net amort premium accret discount market debt secur
invest
financ
proce exercis stock option
compani report svb leerink equiti research estim
scenario risdiplam succe type ii/iii sma
scenario risdiplam fail type ii/iii sma
royalti
ww royalties/profit share p/w
total p/w royalti
compani report svb leerink equiti research estim
univers pennsylvania
univers minnosota
compani report svb leerink equiti research estim
